PA
AMAG

Perceptive Advisors’s AMAG Pharmaceuticals AMAG Stock Holding History

Perceptive Advisors’s Portfolio AMAG Stock Details AMAG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-560,000
Closed -$12.6M – 174
2017
Q1 		$12.6M Buy
560,000
+540,476
+2,768% +$12.9M 0.72% 36
2016
Q4 		$679K Hold
19,524
– – 0.05% 103
2016
Q3 		$479K Buy
+19,524
New +$488K 0.03% 132
2015
Q4 		– Sell
-2,904
Closed -$115K – 184
2015
Q3 		$115K Buy
+2,904
New +$180K 0.01% 148

Other funds holding AMAG

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Perceptive Advisors's AMAG Position: Q2 2017 in Review

Perceptive Advisors sold out of AMAG Pharmaceuticals (AMAG) in Q2 2017, closing a stake of 560,000 shares — an estimated $12.6M sold.

Perceptive Advisors first reported a position in AMAG in Q3 2015 and held it in 4 quarters. The position peaked at $12.6M in Q1 2017. 174 funds tracked by Wall St. Rank hold AMAG as of Q2 2017.

  • Perceptive Advisors reported no remaining AMAG Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Perceptive Advisors sold 560,000 AMAG Pharmaceuticals shares in Q2 2017, an estimated $12.6M.
  • Perceptive Advisors first reported a position in AMAG Pharmaceuticals in Q3 2015 and held it in 4 quarters.
  • Perceptive Advisors's AMAG Pharmaceuticals position peaked at $12.6M in Q1 2017.
  • 174 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q2 2017.

Based on Perceptive Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.